As shareholders we have better insight into the pr
Post# of 36508
![](/assets/46931549/no_avatar_available_thumb.jpg)
Priorities:
10K, S1,Uplisting to NASDAQ, and the Spinout (NGIO?)
Process:
What requirements are necessary for a company that is relisting to NASDAQ (Generex) compared to a company that has never been listed?
In relisting, if a company with a history on NASDAQ exceeds its requirements for shareholder count, board lots, and other major areas of compliance, what is the impact of failing to meet the $2 pricing rule?
That's my interpretation, and I think it lends some clarity to the situation. However, there are questions that need to be answered by Donohoe and NASDAQ. Comments?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)